Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05981170
Other study ID # ICO-2022-20
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 2023
Est. completion date March 2025

Study information

Verified date May 2023
Source Institut Cancerologie de l'Ouest
Contact Loïc FAIVRE
Phone (0)2 41 35 27 00
Email loïc.faivre@ico.unicancer.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Physical activity (PA) has been an integral part of non-drug therapy since the early 2010s. This supportive care is likely to reduce fatigue and improve the quality of life of patients during and after the cancer treatment phase. Physical activity also has a protective effect in terms of tertiary prevention by reducing the risk of recurrence of certain cancers (breast, colon, prostate) by around 40 to 50% and by reducing overall mortality. Adapted physical activity (APA) is offered at the Institut de Cancérologie de l'Ouest (ICO) in Angers, but there are obstacles particularly linked to the geographical distance of the establishment where this activity is offered. The RAPASS project is a prospective study which will be proposed to patients followed at the ICO, living in rural areas and far from Angers. Its main objective is to describe the fatigue and quality of life of patients before, during and after a 13-session home-based APA programme. The data collected will also be used to describe changes in physical condition and level, compliance with the programme, continuation of physical activity beyond the duration of the programme, and satisfaction.


Description:

The oncologist first assesses the patient's need for APA. The patient is then seen by the ICO's APA coach (EAPA) who presents the APA programme. If the patient agrees to participate, the coach assesses the patient's physical capacity in order to adapt the programme to their needs. The programme is then carried out with the departmental sports for all committee 49. The frequency of practice will ideally be one session per week at the patient's home, supervised by a coach from Departmental Committee for Sport for All in 49. A total of 13 sessions will be carried out. The sessions will aim to develop all the components of physical fitness (endurance, strength, balance, flexibility, coordination, etc.). The patient receives a walking logbook to record the number of daily steps taken, an exercise booklet to work independently and a pedometer. In the presence of the coach, the patients perform different exercises and complete different questionnaires. The programme is evaluated by the ICO EAPA 3 months after the 13th and final session.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 10
Est. completion date March 2025
Est. primary completion date March 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Performans Status = 2 - Patient living in a rural area - Patient with a brain tumour and/or metastatic cancer - Patient with a medical prescription for APA practice - Patient with a certificate of no contraindication to physical activity Exclusion Criteria: - Persons deprived of their liberty, under court protection, under guardianship or under the authority of a guardian - Patient unable to undergo the trial procedures for social or psychological reasons - Patient who does not understand French

Study Design


Intervention

Other:
Adapted physical activity at home
The programme will take place over 6 months and will include : 1 consultation with the oncologist who will first assess the need for Adapted Physical Activity and then prescribe the APA with a certificate of no physical contraindication 1 consultation with the ICO's APA coach who will present the APA programme and assess the patient's physical capacity using the Short Physical Performance Battery (SPPB) test in order to adapt the programme to their needs. 13 home-based APA sessions (ideally one session per week) with the EAPA from Departmental Committee for Sport for All in 49 1 telephone call with the EAPA of the ICO to evaluate the programme 3 months after the last session. Patients will also be asked to complete questionnaires at the first session (S1), halfway through the sessions (S6) and at the last session (S13). These are FACIT-F 5Functional Assessment of Chronic Illness Therapy - Fatigue ; Ricci and L. Gagnon ; P-GIC (Patients' Global Impression of Change (PGIC) scale)

Locations

Country Name City State
France Institut de Cancerologie de L'Ouest Angers

Sponsors (1)

Lead Sponsor Collaborator
Institut Cancerologie de l'Ouest

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) To describe the fatigue (physical, functional, social, emotional components) of patients.
The Score from FACIT-F range from 0 to 52. The higher the score, the lower is the fatigue.
Through study completion, an average 6 months.
Secondary Short Physical Performance Battery test (SPPB) It is used to assess the physical performance of an individual. It is the result of the scores of three criteria: the balance test, the walking speed test and the chair lift test.
The sum of the scores of all the tests gives an overall performance score:
SPPB 0-6: Poor performance
SPPB 7-9: Intermediate performance
SPPB 10-12: High performance
Through studied intervention, an average 3 months.
Secondary 6 minute walk test This test measures the functional limitation by comparing the theoretical distance with the measured distance. The patient is asked to walk as far as possible within six minutes:
Excellent functional mobility =91% of the theoretical distance
Good functional mobility between 82% and 90% of the theoretical distance
Moderate functional limitation between 74% and 82% of the theoretical distance
Severe functional limitation =73% of the theoretical distance
Through studied intervention, an average 3 months.
Secondary Hand grip test This test measures muscular health of the hands and forearms. Through studied intervention, an average 3 months.
Secondary Flexibility test The patient performs a standing trunk flexion with legs stretched. Depending on the area reached (hand touching the ground, kick, tibia, etc.), a score will be given on a scale of 1 to 5, which differs according to the patient's sex. Through studied intervention, an average 3 months.
Secondary Balance test The patient is asked to stand on one leg for 1 minute with their eyes open. The best time is recorded and depending on the age and sex of the patient, his or her performance will be rated on a scale of 1 (very poor balance) to 4 (excellent balance). Through studied intervention, an average 3 months.
Secondary Ricci et Gagnon questionnaire This questionnaire assesses the level of physical activity.
A number of points ranging from 1 to 5 are assigned to each answer. The total sum of the points determines an overall score that classifies the patients into :
Score < 18 : inactive
18 = Score = 35: active
Score > 35: very active
Through study completion, an average 6 months.
Secondary The Patient Global Impression scale (P-GIC) Evaluates the patient's satisfaction with the implementation of a home-based APA programme.
The questionnaire includes a single question asking the patient what change home-based APA has had on their overall quality of life. The patient is given 7 options from which to choose the one that best corresponds to the perceived change: Very strongly positive, Strongly positive, Slightly positive, No change, Slightly negative, Strongly negative, Very strongly negative.
At the end of the APA sessions, on average 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT03058809 - Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A
Active, not recruiting NCT00436735 - Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors Phase 1